Navigation Links
New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
Date:10/24/2007

k at least one dose of treatment, found that treatment-emergent adverse events were reported in approximately 63% of AMBIEN CR-treated patients compared to 50% of patients treated with placebo. Serious adverse events were reported in approximately 3% of study patients taking AMBIEN CR compared to approximately 2% of patients treated with placebo. These adverse events were not considered by the investigator to be related to the study treatment.

About Insomnia

Insomnia can be a serious medical condition characterized by difficulty falling asleep, waking up often during the night and having trouble going back to sleep, waking up too early in the morning and feeling tired upon waking. More than 30 million Americans are affected by chronic insomnia each year.

Patients with chronic insomnia report higher rates of absenteeism and demonstrate poor work efficiency compared to normal sleepers. Chronic and occasional insomniacs were both more likely to doze off during daytime activities or when bored, and to take naps than individuals who do not experience insomnia. Insomnia can lead to stress and reduced productivity, and thus may be costly to the workplace.

About AMBIEN CR

AMBIEN CR is the first and only dual-layer, extended-release prescription sleep medication indicated to help induce and maintain sleep with no significant decrease in next-day performance. AMBIEN CR is delivered in two stages. The first layer dissolves quickly to induce sleep. The second layer is released more gradually into the body to help provide more continuous sleep.

Important Safety Information

AMBIEN CR is a treatment option you and your healthcare provider can consider along with lifestyle changes and can be taken for as long as your provider recommends. Until you know how AMBIEN CR will affect you, you shouldn't drive or operate machinery. Be sure you're able to devote 7 to 8 hours to sleep before being active again. Sleepwalking, and eating or driving whi
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)... 2014 With advancements in neurological and ... is seeing new growth, according to Kalorama Information. ... for the majority of market volume, newer 3T ... which are creating opportunities for more sophisticated applications. The ... at a rate of 4%, with world market ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... Papastavros, Associates has opened a new diagnostic imaging center ... while two Newark centers offer CT, Open MRI and digital ... centers throughout Delaware , plus a number of walk-in X-ray ... The new imaging center in north Wilmington, ...
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) announced ... of 8,184,556 units in a registered direct offering to ... investors for a per unit purchase price of $2.75, ...  Each unit consists of one share of common stock, ...
Cached Medicine Technology:Papastavros Opens New Radiology Centers in Delaware 2ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing 2ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing 3
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... The American Society for Radiation Oncology (ASTRO) has ... funded by the Radiation Oncology Institute the ... Residents/Fellows in Radiation Oncology Research Seed Grant Award. ... , The Junior Faculty Career Research Training Award ...
... of Health announce that the Consortium of Food Allergy ... five more years. CoFAR will continue to foster new ... expand in scope to include research on the genetic ... eosinophilic gastrointestinal diseases (EGIDs). Funding for CoFAR is ...
... determine how arsenic increases the risk of lung cancer ... researcher will use $1.7 million in federal funding during ... disrupt cells, leading to the disease. Chengfeng Yang, ... Medicine and MSU,s Center for Integrative Toxicology, will be ...
... -- Children,s National Medical Center, in partnership ... a prestigious Clinical and Translational Science Award (CTSA) from ... Institutes of Health. This award, which totals ... given directly to a children,s hospital. The Clinical ...
... alarming increase of morbidly obese diabetics is causing more new ... Charcot foot can make walking difficult or impossible, and in ... that secures foot bones with an external frame has enabled ... according to Loyola University Health System foot and ankle surgeon ...
... updated guidelines on recommended vitamin D intake have been published ... Medical Association Journal ( CMAJ ). Dr. David ... and member of Osteoporosis Canada,s (OC) Scientific Advisory Council, is ... Canada. "OC,s current recommendations on vitamin D intake for ...
Cached Medicine News:Health News:5 awarded ASTRO research grants 2Health News:NIH expands food allergy research program 2Health News:NIH expands food allergy research program 3Health News:Researcher targets gene regulators on link between arsenic, cancer 2Health News:Children's National Medical Center receives first NIH CTSA given to a children's hospital 2Health News:Children's National Medical Center receives first NIH CTSA given to a children's hospital 3Health News:New treatment for crippling diabetic Charcot foot 2Health News:New vitamin D guidelines 2
PremierEdge™ Implant Knives....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: